PSMA PET/CT联合前哨淋巴结活检用于前列腺癌原发淋巴结分期
该回顾性研究纳入53例中高危初诊前列腺癌患者,术前行PSMA PET/CT后行机器人辅助根治性前列腺切除术及扩大盆腔淋巴结清扫,PSMA PET/CT阴性者加做前哨淋巴结活检。联合两种方法对pN1患者检出灵敏度达100%,总体淋巴结分期准确率94%,前哨淋巴结活检可检出更小的淋巴结转移。
要点
- PSMA PET/CT阴性患者加做前哨淋巴结活检,联合灵敏度达100%。
- 联合两种方法对淋巴结分期准确率为94%。
- 前哨淋巴结活检检出的转移灶直径显著小于PSMA PET/CT。
核心结论
- PSMA PET/CT联合前哨淋巴结活检对中高危初诊前列腺癌淋巴结分期准确率达94%。
- PSMA PET/CT阴性者加做前哨淋巴结活检可将联合灵敏度提升至100%。
研究设计与样本
- 回顾性纳入2017年1月至2019年3月连续53例中高危初诊前列腺癌患者。
- 术前行68Ga或18F-DCFPyL PSMA PET/CT,随后行机器人辅助根治性前列腺切除术及扩大盆腔淋巴结清扫,以ePLND为参考标准。
- PSMA PET/CT阴性者行前哨淋巴结活检,示踪剂为吲哚菁绿-99mTc-纳米胶体或99mTc-纳米胶体联合游离吲哚菁绿。
主要发现
- 53例中22例PSMA PET/CT阳性,31例阴性者接受前哨淋巴结活检。
- 23例(43%)为pN1,其中6例(26%)PSMA PET/CT阴性后经前哨淋巴结活检确认。
- 联合方法检出全部pN1患者,灵敏度100%(95%CI 86%-100%),53例中50例分期正确,准确率94%(95%CI 84%-99%)。
- 前哨淋巴结活检检出转移灶中位直径2.0 mm(IQR 1.0-3.8 mm),小于PSMA PET/CT的5.5 mm(IQR 2.6-9.3 mm),P=0.007。
关键数值与推荐
- 联合PSMA PET/CT与前哨淋巴结活检对pN1检出灵敏度100%(95%CI 86%-100%)。
- 联合方法淋巴结分期准确率94%(95%CI 84%-99%)。
- 前哨淋巴结活检转移灶中位直径2.0 mm(IQR 1.0-3.8 mm),PSMA PET/CT为5.5 mm(IQR 2.6-9.3 mm),P=0.007。
临床怎么用
- 对中高危初诊前列腺癌,PSMA PET/CT阴性者可加做前哨淋巴结活检以提高淋巴结分期准确性。
- 联合分期结果可能为后续治疗决策提供信息,如以PSMA PET/CT联合前哨淋巴结活检替代ePLND作为放疗前分期的首选方法。
局限性
- 回顾性研究设计。
- 样本量53例,前哨淋巴结活检亚组31例。
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our objective was to determine the diagnostic capabilities of combined prostate-specific membrane antigen (PSMA) PET/CT and sentinel node (SN) biopsy in PSMA PET/CT-negative patients for primary lymph node (LN) staging in prostate cancer (PCa) patients. Methods: Between January 2017 and March 2019, retrospectively, all consecutive patients with diagnosed intermediate- or high-risk primary PCa who underwent preoperative PSMA PET/CT (68Ga or 18F-DCFPyL) followed by robot-assisted radical prostatectomy and extended pelvic LN dissection (ePLND) were included. All patients without suspected LN metastases on PSMA PET/CT were considered candidates for SN biopsy with indocyanine green-99mTc-nanocolloid or 99mTc-nanocolloid with free indocyanine green used as tracers. The ePLND was used as a reference standard. Results: Of 53 patients, 22 had positive PSMA PET/CT results and 31 underwent subsequent SN biopsy after negative PSMA PET/CT results. In total, 23 patients (43%) were pN1, of whom 6 (26%) had negative PSMA PET/CT results and underwent subsequent SN biopsy. The combined use of SN biopsy and PSMA PET/CT identified all pN1 patients (100% sensitivity; 95% confidence interval, 86%-100%) and performed correct nodal staging in 50 of 53 patients (94% diagnostic accuracy; 95% confidence interval, 84%-99%). SN biopsy identified significantly smaller LN metastases (median diameter, 2.0 mm; interquartile range, 1.0-3.8 mm) than PSMA PET/CT (median diameter, 5.5 mm; interquartile range, 2.6-9.3 mm; P = 0.007). Conclusion: Combining both modalities led to a 94% accuracy for nodal staging in diagnosed intermediate- and high-risk primary PCa. Adding SN biopsy in patients with negative PSMA PET/CT results increased the combined sensitivity to 100% for detecting nodal metastases at ePLND. This diagnostic accuracy may provide valuable information for directing further treatment in PCa patients, such as the use of PSMA PET/CT and SN biopsy rather than ePLND as the preferred approach for staging before radiotherapy.
引用
- Hinsenveld FJ, Wit EMK, van Leeuwen PJ, et al. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer. J Nucl Med. 2019. PMID: 31562222. doi:10.2967/jnumed.119.232199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。